CAMRF (Camurus AB) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAMRF Camurus AB CAMRF
81 GF Score
Price $58.51
GF Value $83.66
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Short-term investments?

Short-term investments only applies to insurance companies.

CAMRF
81GF Score
Camurus AB CAMRF
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $58.51 is trading 30.1% below its estimated GF Value™ of $83.66. GuruFocus considers Camurus AB to be Significantly Undervalued.

Key valuation signals for CAMRF:

  • Short-term investments:
  • GF Value™: $83.66 vs. price of $58.51 (30.1% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score

Get the complete analysis for CAMRF

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.51
Price
$83.66
GF Value